Trials / Completed
CompletedNCT02488421
Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany, UK and France: REACT-AF2
Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany, UK and France: REACT-AF 2
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 38,122 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine and compare the persistence rate of newly prescribed apixaban, rivaroxaban, dabigatran and VKAs in patients with NVAF.
Detailed description
Actual number of patients enrolled for UK : 15242 patients Actual number of patients enrolled for Germany : 22880 patients
Conditions
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2016-07-01
- Completion
- 2016-07-01
- First posted
- 2015-07-02
- Last updated
- 2016-12-20
Source: ClinicalTrials.gov record NCT02488421. Inclusion in this directory is not an endorsement.